Chemoradiotherapy of NSCLC Stage IIIB

Randomized Phase II Study Evaluating an Induction Chemotherapy Followed by a Concomitant Chemoradiotherapy and a Concomitant Chemoradiotherapy Followed by a Consolidation Chemotherapy Among Patients With NSCLC Stage III Not Resectable

To evaluate the best timing of the concomitant chemoradiotherapy among patients with NSCLC stage III not resectable treated by concomitant chemo-radiotherapy, either preceded by a induction chemotherapy, or followed by a consolidation chemotherapy.

Chemotherapy:

C = Cisplatine : 80 mg/m² P = Paclitaxel : 200 mg/m² N = Vinorelbine : 15 mg/m²

Radiotherapy:

66 Gy with 33 fractions (2 Gy/fraction, 1 fraction/day, 6,5 weeks) High energy Photons X (>= 9MV)

Inclusion Criteria:

• NSCLC stage IIIA N2 or IIIB not resectable, except N3 sus-clavicular, nor reached pleural
• PS = 0 or 1
• Possibility of including all the targets in only one exposure field
• Slimming < 10% of the weight of the body
• Functions hepatic, renal and hematologic normal
• VEMS >40% and PaO2 >60 mmHg
• written and signed informed consent

Exclusion criteria :

- NSCLC stage IV or wet-IIIB